It is the broad, long-term goal of this program to build on and extend the current knowledge in the field of bone marrow transplantafion and hematological malignancies. This program is a mulfidisciplinary clinical, basic and translational research effort whose overall goal is to improve outcomes for patients with solid and liquid malignancies. To this end, the investigators of this application will ufilize the approach of translational research, bridging the novel experimental concepts and observations made at the laboratory bench to clinical applicafion at the pafients'bedsides. In both basic and clinical areas, the HCTHM Program fosters interacfions between many Programs and members of the DCCI. The Program includes 35 members from 11 basic and clinical departments within Duke University. Total funding for program members is $68,881,117, of which $64,009,143 is from peer- reviewed sources. A cancer focus is illustrated by $976,102 or 1.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004- 2008, program members published 706 papers in peer-reviewed journals cited in PubMed. Of these publicafions, 6.4% are the result of intra-programmatic collaborations and 13% due to inter-programmafic collaborations.
The aims of the Program are: 1. To optimize the use of allogeneic and autologous transplantation of hematopoiefic stem cells. 2. To use and compare various alternative sources of hematopoietic stem cells for allogeneic transplantation. 3. To develop novel preparatory regimens for allogeneic stem cell transplantation. 4. To understand the basic biology of graft versus tumor (GvT) and to explore new ways to induce GvT effects following transplantation. 5. To study the nature of and define the problems associated with hematopoiefic and immunologic reconstitution after allogeneic transplantation with the overall goal of developing novel supportive care measures for patients transplanted with stem cells from alternative and mismatched donors. 6. To understand hematopoietic stem cell development and control of differentiation. 7. To promote effective interactions of the members of the Duke Comprehensive Cancer Institute that will stimulate new translational research efforts to improve the care of patients with hematologic malignancies. 8. To identify new cellular and stromal targets for therapy with antibodies or small molecules, leading to evaluafion of various labeling techniques, such as using radiolabels or diphtheria toxins, of small molecules and antibodies with subsequent clinical evaluation of safety and efficacy. 9. To evaluate the importance of different signaling mechanisms in leukemogenesis or lymphomagenesis.
|Adams, Rebecca N; Mosher, Catherine E; Blair, Cindy K et al. (2015) Cancer survivors' uptake and adherence in diet and exercise intervention trials: an integrative data analysis. Cancer 121:77-83|
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6|
|Batinic-Haberle, Ines; Tovmasyan, Artak; Roberts, Emily R H et al. (2014) SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal 20:2372-415|
|Sachdeva, Mohit; Mito, Jeffrey K; Lee, Chang-Lung et al. (2014) MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest 124:4305-19|
|Tovmasyan, Artak; Carballal, Sebastian; Ghazaryan, Robert et al. (2014) Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents. Inorg Chem 53:11467-83|
|Azrad, Maria; Demark-Wahnefried, Wendy (2014) The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Curr Nutr Rep 3:9-15|
|Blair, Cindy K; Madan-Swain, Avi; Locher, Julie L et al. (2013) Harvest for health gardening intervention feasibility study in cancer survivors. Acta Oncol 52:1110-8|
|Mito, Jeffrey K; Min, Hooney D; Ma, Yan et al. (2013) Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 229:132-40|
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2013) Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 40:52-9|
|Hover, Bradley M; Loksztejn, Anna; Ribeiro, Anthony A et al. (2013) Identification of a cyclic nucleotide as a cryptic intermediate in molybdenum cofactor biosynthesis. J Am Chem Soc 135:7019-32|
Showing the most recent 10 out of 161 publications